Literature DB >> 23417747

Poor prognosis of uterine serous carcinoma compared with grade 3 endometrioid carcinoma in early stage patients.

Ji Young Park1, Joo-Hyun Nam, Young-Tak Kim, Yong-Man Kim, Jong-Hyeok Kim, Dae-Yeon Kim, Insuk Sohn, Shin-Wha Lee, Chang Ohk Sung, Kyu-Rae Kim.   

Abstract

Difference in prognosis between grade 3 endometrioid carcinoma (G3EC) of the endometrium and uterine serous carcinoma (USC) is controversial. In this study, we further evaluated the difference in prognosis, if any, between G3EC (n = 61) and USC (n = 47) on a total of 565 patients with endometrial cancer. In addition, meta-analysis was performed using data from seven previous publications (n = 8,637) and from the Asan Medical Center (n = 108). Regarding the cases from our institution, USC tended to occur in older patients (≥65 years) than G3EC (P = 0.011). Deep myometrial invasion (more than or equal to half) was more frequently identified in G3EC (36/61, 59.0 %) than in USC (17/47, 36.2 %) (P = 0.021). Between patients with early stage G3EC and USC (stages I and II), there were no significant differences in any clinicopathological parameter, but there was a significant difference in overall survival (P = 0.017) that was not found in advanced stage (P = 0.588). USC was an independent prognostic factor for poor overall survival (hazard ratio, 6.125; P = 0.030) in early stage patients. In the meta-analysis on 5-year survival in patients with early stage cancers, which also included our study results, a higher relative risk (1.92, 95 % CI 1.62-2.27) was demonstrated in USC than in G3EC (P < 0.001). In conclusion, our study reveals that USC is associated with a poorer prognosis compared with G3EC, only in patients with early stage carcinoma, suggesting that different treatment strategies should be considered according to the histologic type in order to improve treatment outcome.

Entities:  

Mesh:

Year:  2013        PMID: 23417747     DOI: 10.1007/s00428-013-1382-8

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  27 in total

1.  Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium.

Authors:  P Mhawech-Fauceglia; R F Herrmann; J Kesterson; I Izevbaye; S Lele; K Odunsi
Journal:  Eur J Surg Oncol       Date:  2010-12       Impact factor: 4.424

2.  The dualistic model of endometrial cancer: the challenge of classifying grade 3 endometrioid carcinoma.

Authors:  Gian Franco Zannoni; Giovanni Scambia; Daniela Gallo
Journal:  Gynecol Oncol       Date:  2011-10-19       Impact factor: 5.482

Review 3.  Endometrial cancer.

Authors:  Frederic Amant; Philippe Moerman; Patrick Neven; Dirk Timmerman; Erik Van Limbergen; Ignace Vergote
Journal:  Lancet       Date:  2005 Aug 6-12       Impact factor: 79.321

4.  The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.

Authors:  F D Cirisano; S J Robboy; R K Dodge; R C Bentley; H R Krigman; I S Synan; J T Soper; D L Clarke-Pearson
Journal:  Gynecol Oncol       Date:  2000-04       Impact factor: 5.482

5.  Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium.

Authors:  William T Creasman; Matthew F Kohler; Franco Odicino; Patrick Maisonneuve; Peter Boyle
Journal:  Gynecol Oncol       Date:  2004-12       Impact factor: 5.482

6.  Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study.

Authors:  Gian Franco Zannoni; Valerio Gaetano Vellone; Vincenzo Arena; Maria Grazia Prisco; Giovanni Scambia; Arnaldo Carbone; Daniela Gallo
Journal:  Virchows Arch       Date:  2010-06-15       Impact factor: 4.064

Review 7.  Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium.

Authors:  J L Burton; M Wells
Journal:  Histopathology       Date:  1998-10       Impact factor: 5.087

8.  Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?

Authors:  David M Boruta; Paola A Gehrig; Pamela A Groben; Victoria Bae-Jump; John F Boggess; Wesley C Fowler; Linda Van Le
Journal:  Cancer       Date:  2004-11-15       Impact factor: 6.860

9.  Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation.

Authors:  S F Lax; E S Pizer; B M Ronnett; R J Kurman
Journal:  Hum Pathol       Date:  1998-09       Impact factor: 3.466

10.  Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers.

Authors:  C A Hamilton; M K Cheung; K Osann; L Chen; N N Teng; T A Longacre; M A Powell; M R Hendrickson; D S Kapp; J K Chan
Journal:  Br J Cancer       Date:  2006-03-13       Impact factor: 7.640

View more
  4 in total

1.  Role of Morphometry and Matrix Metalloproteinase-9 Expression in Differentiating between Atypical Endometrial Hyperplasia and Low Grade Endometrial Adenocarcinoma

Authors:  Magda I Assaf; Wafaa Abd El-Aal; Samah S Mohamed; Noha N Yassen; Eman A Mohamed
Journal:  Asian Pac J Cancer Prev       Date:  2018-08-24

2.  The Impact of Adjuvant Management Strategies on Outcomes in Women With Early Stage Uterine Serous Carcinoma.

Authors:  Andrew Cook; Remonda Khalil; Charlotte Burmeister; Irina Dimitrova; Mohamed A Elshaikh
Journal:  Cureus       Date:  2021-02-23

3.  What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience.

Authors:  Michalis Liontos; Anna Svarna; Charalampos Theofanakis; Oraianthi Fiste; Angeliki Andrikopoulou; Maria Kaparelou; Konstantinos Koutsoukos; Nikolaos Thomakos; Dimitrios Haidopoulos; Alexandros Rodolakis; Meletios Athanasios Dimopoulos; Flora Zagouri
Journal:  Curr Oncol       Date:  2021-11-20       Impact factor: 3.677

4.  The expression pattern of 19 genes predicts the histology of endometrial carcinoma.

Authors:  Chang Ohk Sung; Insuk Sohn
Journal:  Sci Rep       Date:  2014-06-04       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.